Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Meloxicam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 4/20 | 0.98 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | GLA | P06280 | 1/20 | 0.98 |
| ▸ | EDNRA | P25101 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | PKM | P14618 | 2/20 | 0.76 |
| ▸ | THPO | P40225 | 1/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.76 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meloxicam SCHEMBL3576 | 0.99 | PTGS1 (1.00) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL3752395 | 0.99 | PTGS1 (1.00) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL23589638 | 0.99 | PTGS1 (1.00) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL332206 | 0.98 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL20168549 | 0.98 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL20168506 | 0.98 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL3373822 | 0.98 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL20165003 | 0.98 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL2352397 | 0.98 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL7898655 | 0.98 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200078333-A1 | Healthier Aging in Domesticated Animals | POSTREL RICHARD (US) | 2020-03-12 | — | — | US | claimed |
| CN-109806228-A | A kind of solution containing meloxicam liposome | 北京泰德制药股份有限公司 | 2019-05-28 | — | — | CN | claimed |
| US-20190030044-A1 | HUMAN LIFE EXTENSION THERAPY THROUGH MOLECULAR, CELLULAR AND SUBCELLULAR MANAGEMENT OF BIOCHEMICAL REQUIREMENTS OF MITOCHONDRIA AND OF OTHER ORGANELLE PROCESSES ASSOCIATED WITH THE ADVENT OF DISEASE AND/OR AGING | POSTREL RICHARD (US) | 2019-01-31 | — | — | US | claimed |
| US-20190029993-A1 | QUALITY OF LIFE EXTENSION THERAPIES RELATING TO AGING, FOOD ALLERGIES, PAIN AND REDUCED VIGOR BY MANAGING MOLECULAR, CELLULAR AND SUBCELLULAR BIOCHEMICAL REQUIREMENTS OF MITOCHONDRIA AND OTHER ORGANELLE PROCESSES | REVIGORON LLC | 2019-01-31 | — | — | US | claimed |
| WO-2018118197-A1 | HEALTHIER AGING IN DOMESTICATED ANIMALS | POSTREL RICHARD (US) | 2018-06-28 | — | — | WO | claimed |
| US-20180168932-A1 | Meloxicam Dosage Forms | APOTEX TECH INC (CA) | 2018-06-21 | — | — | US | claimed |
| US-20130274235-A1 | TREATMENT OF MOTOR NEURON DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2013-10-17 | — | — | US | claimed |
| WO-2012069842-A1 | COMBINATION OF A CYSLT1 ANTAGONIST WITH AN ANTI -ARTHRITIC DRUG FOR THE TREATMENT OF ARTHRITIC DISORDER | XARAGEN PHARMA LIMITED (GB) | 2012-05-31 | — | — | WO | claimed |
| WO-2012048330-A2 | TREATMENT OF MOTOR NEURON DISEASE | THE MCLEAN HOSPITAL CORPORATION (US) | 2012-04-12 | — | — | WO | claimed |
| US-20240216295-A1 | Anti-Aging Therapy for Humans and Other Mammals | POSTREL RICHARD (US) | 2024-07-04 | — | — | US | disclosed |
| US-20230404942-A1 | Life Extension and Quality of Life Improvement for Humans | POSTREL RICHARD (US) | 2023-12-21 | — | — | US | disclosed |
| CN-111511350-B | Compositions for parenteral administration of therapeutic agents | 埃皮辛特瑞柯斯公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20230114740-A1 | Life Extension and Quality of Life Improvement for Humans and Other Mammals | POSTREL RICHARD (US) | 2023-04-13 | — | — | US | disclosed |
| CN-112823787-B | Injection containing meloxicam and preparation method thereof | 北京泰德制药股份有限公司 | 2023-02-21 | — | — | CN | disclosed |
| US-20090076019-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE | MOUNT SINAI HOSPITAL (CA) | 2009-03-19 | — | — | US | disclosed |
| CN-101090900-A | Process for preparation of high-purity meloxicam and meloxicam potassium salt | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2007-12-19 | — | — | CN | disclosed |
| EP-1828178-A1 | PROCESS FOR PREPARATION OF HIGH-PURITY MELOXICAM AND MELOXICAM POTASSIUM SALT | EGIS GYOGYSZERGYAR RT. (HU) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006064298-A1 | PROCESS FOR PREPARATION OF HIGH-PURITY MELOXICAM AND MELOXICAM POTASSIUM SALT | EGIS GYÓGYSZERGYÁR NYRT. (HU) | 2006-06-22 | — | — | WO | disclosed |
| US-6869948-B1 | Meloxicam for oral administration | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-03-22 | — | — | US | disclosed |
| WO-2004062552-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A NSAID AND A BENZIMIDAZOLE DERIVATIVE | GALEPHAR M/F (BE) | 2004-07-29 | — | — | WO | disclosed |